Loading company…
Xunbaihui Biotechnology develops oncology drugs and platforms for cancer research.
Founded in 2016 in Shanghai, Xunbaihui Biotechnology focuses on cancer diagnosis and treatment. Its products include oncology antibody drugs XBH25, XBH62, and XBH82, plus genomics and AI platforms for tumor target tracking and antibody drug research. In October 2021, the company closed a Series B round led by Coatue Management, with IDG Capital, Watson Capital, Linear Capital, and 3W Investment participating. Founder Xiaole Liu is a professor at Harvard University and Dana Farber Cancer Institute.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in